ESC Congress 2020 - European Society of Cardiology Listing | Page 2 of 2

Icosapent ethyl associated with plaque regression

Small trial shows regression of several plaque components, authors report.

The drug has potential for people with renal disease in need of improved treatment options, investigators say.

But the study, PARALLAX, found no benefit in a six-minute walk test, researchers say.

The benefit was seen regardless of the presence of type 2 diabetes, researchers say.

Chinese study found a composite outcome was significantly better in those on the therapy.

It's the only longer-term trial of digoxin for AF despite the drug being used since 1785, authors say.

The randomised trial examining clinical utility of colchicine in acute coronary syndrome failed to find a benefit in reduced CV events.

The results show the benefit of disease-targeted therapy, researchers say.